Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company, 巨子生物 (2367.HK), reported a slight decline in revenue and profit for the year ending December 31, 2025, with total revenue of 55.19 billion yuan, down 0.37% year-on-year, and a net profit of 19.15 billion yuan, down 7.15% year-on-year [1]. - The company's gross margin was 80.34%, a decrease of 1.76 percentage points compared to the previous year, while the net profit margin fell to 34.70%, down 2.54 percentage points year-on-year [1]. - The second half of 2025 saw a significant impact from public sentiment issues, leading to a revenue drop of 19.76% and a net profit decline of 32.10% [1]. - The company is recognized as a leading player in the global recombinant collagen market, focusing on research and development to expand its eight consumer brands [4]. Financial Performance Summary - For 2025, the company achieved a revenue of 55.19 billion yuan, with a year-on-year decrease of 0.37%, and a net profit of 19.15 billion yuan, reflecting a 7.15% decline [1][6]. - The company forecasts net profits for 2026, 2027, and 2028 to be 19.49 billion yuan, 21.34 billion yuan, and 23.45 billion yuan, respectively, with corresponding price-to-earnings ratios of 15, 14, and 12 times [4][6]. - The revenue is expected to grow to 61.17 billion yuan in 2026, representing a year-on-year increase of 10.85% [6].
巨子生物：双美业态起航，期待2026年重返增长轨道-20260322